UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2018
Commission File No. 001-38691
AURORA CANNABIS INC.
(Translation of registrant's name into English)
500 - 10355 Jasper Avenue
Edmonton, Alberta, T5J 1Y6, Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☐ Form 40-F ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) ☐
SUBMITTED HEREWITH
| Exhibits | Description | |
| 99.1 | Form 51-102F3 - Material Change Report dated December 7, 2018 | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AURORA CANNABIS INC.
/s/ Glen Ibbott
Glen Ibbott
Chief Financial Officer
Date: December 7, 2018
Exhibit 99.1
FORM 51-102F3
MATERIAL CHANGE REPORT
| Item 1. | Name and Address of Company |
| Aurora Cannabis Inc. (“ Aurora ” or the “ Company ”) | |
| 500 - 10355 Jasper Avenue | |
| Edmonton, Alberta | |
| T5J 1Y6 | |
| Item 2. | Date of Material Change |
| November 14, 2018. | |
| Item 3. | News Release |
| A news release with respect to the material change referred to in this report was issued in Canada through the facilities of Canada Newswire and filed on SEDAR on November 14, 2018. | |
| Item 4. | Summary of Material Change |
| On November 14, 2018, the Company announced the appointment of Dr. Jonathan Page as Chief Science Officer. | |
| Item 5. | Full Description of Material Change |
| 5.1 Full Description of Material Change |
On November 14, 2018, the Company announced inter alia , as follows:
The appointment of Dr. Jonathan Page, PhD as the Company’s Chief Science Officer .
In this new role, Dr. Page will oversee all science-related projects at the Company. The Aurora science team develops innovative products for the medical, wellness and adult consumer markets and focuses on delivering industry-leading cultivation results in terms of yields, consistency, quality and efficiency.
Dr. Page is a globally renowned cannabis scientist, with 37 peer-reviewed publications, who was the co-lead of the Canadian team of scientists who first sequenced the cannabis genome. His work also helped discover the biochemical pathways leading to the major cannabinoids. Prior to his appointment, Dr. Page served as CEO of recently acquired Anandia Labs, the world-leading cannabis-focused science company he co-founded.
Aurora has ingrained scientific methods throughout the Company, which it uses to drive efficiencies, medical and plant discovery and product innovation. That approach will only increase with Dr. Page’s appointment. With more than 40 PhD- and MSc-level researchers, Aurora has cutting-edge research programs designed to develop competitive advantages.
An entrepreneurial scientist, Dr. Page co-founded Anandia Labs, which specializes in cannabis genetics, metabolite profiling, plant breeding, disease characterization, and cultivar certification, as well as providing third party independent testing services to producers and patient-cultivators. Dr. Page is an adjunct professor in the Botany Department at the University of British Columbia (UBC) who received his PhD from UBC, undertook postdoctoral training in Germany, and for a decade directed a lab at the National Research Council.
Dr. Page is also an accomplished inventor with eight issued patents or patent applications, and a frequent lecturer on cannabis science at international conferences.
Anandia will continue to operate independently of Aurora. Dr. John Coleman, PhD will be taking over as President at Anandia.
| 5.2 |
Disclosure for Restructuring Transactions
|
| Not applicable. | |
| Item 6. | Reliance on Subsection 7.1(2) of National Instrument 51-102 |
| Not applicable. | |
| Item 7. | Omitted Information |
| Not applicable. | |
| Item 8. | Executive Officer |
| The following senior officer of the Company is knowledgeable about the material change and this Material Change Report and may be contacted: | |
|
Terry Booth, Chief Executive Officer
(604) 362-5207 |
|
| Item 9. | Date of Report |
| December 7, 2018 |